Please note that this meeting will take place as an in-person event in Toronto and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress.

Sunday, October 1, 2023

Welcome and Opening Keynote Lecture

Monday, October 2

Plenary Session 1: T-cell Biology
Plenary Session 2: Macrophages and Myeloid Cells
Plenary Session 3: Inhibitory Cells

Tuesday, october 3

Plenary Session 4: Lymphocyte Subsets Impacting Anti-tumor Immunity
Plenary Session 5: Metabolic Modulation of Anti-tumor Immunity
Plenary Session 6: TCR-targeted Immunotherapies

Wednesday, octoBer 4

Plenary Session 7: Spatial Profiling
Plenary Session 8: Synthetic Biology and Immune Cell Engineering
Plenary Session 9: Engineered Cytokines

Sunday, October 1, 2023

Registration
3-8 p.m. | Metropolitan Ballroom Foyer

Welcome and oPENInG Keynote Lecture
6:30-7:30 P.M. | Metropolitan Ballroom West

Welcome and Opening Keynote Lecture
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, Washington

Keynote Lecture
Chasing T Cell Exhaustion
Crystal L. Mackall, Stanford University School of Medicine, Stanford, California

Opening reception
7:30-9:30 p.m. | Metroplitan ballroom east

Monday, october 2

Continental breakfast
7-8 a.m. | Metropolitan ballroom centre

Plenary Session 1: T-cell Biology
Session Chair: Andrea Schietinger, Memorial Sloan Kettering Cancer center, New York, New York
8-10:05 A.M. | Metropolitan ballroom West

Critical role for Batf3-lineage dendritic cells within the tumor microenvironment
Thomas F. Gajewski, University of Chicago, Chicago, Illinois

Title to be announced
Andrea Schietinger

Elucidating mechanisms of immunotherapy response and resistance in pancreatic cancer
Ingunn Stromnes, University of Minnesota Medical School, Minneapolis, Minnesota

Regulation of exhausted CD8⁺ T cell differentiation by IKZF transcription factors*
Sinead M. Reading, Peter MacCallum Cancer Centre, Melbourne, Australia

Panel Discussion

bREAK
10:05-10:25 A.M. | metropolitan ballroom foyer

pLENARY sESSION 2: MACROPHAGES AND MYELOID CELLS
Session Chair: Jennifer L. Guerriero, Brigham and Women’s Hospital, Boston, MASSACHUSETTS
10:25 A.M.-12:30 p.m. | Metroplitan Ballroom west

Immune archetypes and the shifting paradigms of myeloid biology in cancer
Matthew Krummel, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Decoding clinically distinct multicellular circuits and myeloid phenotypes in cancer
Aaron M. Newman, Stanford University, Stanford, California

Unraveling the complexities of tumor associated macrophages for anti-cancer therapy of breast cancer
Jennifer L. Guerriero

Lyn kinase regulates myeloid-cell responses to mammary tumors*
Joseph T. Greene, Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota

Panel Discussion

Lunch on Own/Free Time
12:30-2:30 P.M.

Plenary session 3: Inhibitory Cells
session chair: pamela S. Ohashi, uhn princess margaret cancer Centre, toronto, ontario, canada
2:30-4:35 p.m. | METROPOLITAN BALLROOM WEST

Hyperactivated CD4⁺ T cells lacking FoxP3 inhibit therapeutics tumor immunity
Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri

Inhibitory ILCs, B7-H3, and anti-tumor immunity
Pamela S. Ohashi

PMN-MDSC in regulation of immune suppressive microenvironment in cancer
Dmitry Gabrilovich, AstraZeneca, Philadelphia, Pennsylvania

Hypoxia promotes inflammatory fibroblast formation in pancreatic cancer*
Ashley M. Mello, University of Michigan, Ann Arbor, Michigan

Panel Discussion

pOSTER SESSION A/RECEPTION
4:45-7:00 P.M. | metropolitan ballroom east

Abstracts to be presented at the conference

eVENING OFF/DINNER ON OWN
7:00 P.M.

tUESDAY, OCTOBER 3

Continental Breakfast
7-8 A.M. | metropolitan ballroom centre

Plenary Session 4: Lymphocyte Subsets Impacting Anti-tumor Immunity
Session Chair: Dario a. a. vignali, University of pittsburgh, Pittsburgh, pennsylvania
8-10:05 A.M. | metropolitan ballroom west

Interferon modification of T cell function and response to immunotherapy
David G. Brooks, University of Toronto, Toronto, Ontario, Canada

Title to be announced
Tak W. Mak, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada

LAG-3: The third checkpoint inhibitor & its synergistic interactions with PD1
Dario A. A. Vignali

Temporal single cell profiling identifies B-cell specific checkpoint molecules that regulate anti-tumor immunity*
Lloyd Bod, Massachusetts General Hospital, Boston, Massachusetts

Panel Discussion

Break
10:05-10:25 A.M. | metropolitan ballroom foyer

Plenary Session 5: Metabolic Modulation of Anti-Tumor Immunity
Session Chair: Greg M. delgoffe, UPMC Hillman cancer center, pittsburgh, pennsylvania
10:25 a.m.-12:30 p.m.

Metabolic modulation during in vitro expansion for curative adoptive cell therapy for cancer
Greg M. Delgoffe

Obesity and immunometabolism in cancer immunotherapy
Jeffrey C. Rathmell, Vanderbilt University Medical Center, Nashville, Tennessee

Tailoring T cell anti-tumor immunity via reprogramming mitochondria-guided transcription networks
Ping-Chih Ho, University of Lausanne, Lausanne, Switzerland

Dgat1 camouflages sexual dimorphism in anti-tumor CD8+ T cell immunity*
Alaa Madi, German Cancer Research Center, Heidelberg, Germany

Panel Discussion

lunch on own/free time
12:30-2:30 p.m.

plenary session 6: tcr-targeted immunotherapies
Session Chair: Catherine j. Wu, dana-farber cancer institute, boston, massachusetts
2:30-4:35 p.m. | metropolitan ballroom west

T cell specificity, phenotype, and dynamics: Impact on cancer immunotherapy
Catherine J. Wu

Cancer Neoantigens: From Discovery to the Clinic
Nina Bhardwaj, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York

Specificity matters: The breadth of endogenous and elicited anti-tumor T cell responses
Paul G. Thomas, St. Jude Children’s Research Hospital, Memphis, Tennessee

Hallmarks of CD8 T cell dysfunction are established within hours of tumor antigen encounter prior to cell division*
Mary Philip, Vanderbilt University Medical Center, Nashville, Tennessee

Panel Discussion

Poster session b/reception
4:45-7 p.m. | metropolitan ballroom east

Posters to be presented at the conference

Evening Off/Dinner on own
7 P.M.

Wednesday, october 4

Continental Breakfast
7-8 a.m. | metropolitan ballroom centre

plenary session 7: spatial profiling
sESSION cHAIR: Brian D. Brown, Icahn School of Medicine at Mount Sinai, New York, New York
8-9:50 a.m. | metropolitan ballroom west

Identifying regulators of tumor immunity by spatial functional genomics
Brian D. Brown

Recirculating tumor-specific T cell responses as biomarkers for virally driven cancers
Evan Newell, Fred Hutchinson Cancer Research Center, Seattle, Washington

Communication is key: Understanding the modulating effect of immune cell crosstalk on T cell therapy function
Amber K. L. Wezenaar, Princess Maxima Centrum, Utrecht, Netherlands

Panel Discussion

Break
9:50-10:05 a.m. | metroplitan ballroom foyer

Plenary session 8: synthetic biology and immune cell engineering
Session Chair: Phillip D. Greenberg, Fred Hutchinson Cancer Research Center, SEattle, Washington
10:05-11:55 a.m. | metropolitan ballroom west

Gene deletions unveiled: Cracking the code for CAR T cell supremacy
Carl H. June, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania

‘Ain’t no mountain high enough’: Making TCR-T cells work against solid tumors 
Philip D. Greenberg

Title to be announced
Michael Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York

Panel Discussion

Break
11:55 a.m.-12:10 p.m. | metropolitan ballroom foyer

plenary session 9: engineered cytokines
Session Chair: Mario Sznol, Yale University, New Haven, Connecticut
12:10-2 p.m. | metropolitan ballroom west

PD1-IL2v: PD-1-Cis IL-2Rβγ agonism yields better T cell effectors from stem-like CD8+ T cells
Pablo Umana, Roche, Schlieren, Switzerland

Restricting the activity of IL-2 and IL-21 to CD8+ T cells greatly enhances their therapeutic potential
Ivana Djuretic, Asher Biotherapeutics, Inc., South San Francisco, California

Challenges in cancer immunotherapy: Connecting the solutions to the problems
Mario Sznol

closing comments and departure
2 p.m. | metropolitan ballroom west

Mario Sznol, Yale University, New Haven, Connecticut

* Short talk from proffered paper